A New Playbook for Ulcerative Colitis: Drugs + Nutraceuticals

Most ulcerative colitis treatments follow a familiar pattern: Start with drugs. Escalate if needed. Hope for response. But there’s a ceiling. Response rates in many clinical trials plateau around 50%.

Now, Evinature is part of a new approach that challenges that model, combining pharmaceuticals with nutraceuticals. And it’s getting serious backing.

A DoD-Backed Clinical Trial with Big Ambitions

A new clinical trial—funded by the U.S. Department of Defense—will test this combination strategy in ulcerative colitis.

Key Details

• Initial funding: $800,000
• Potential total funding: up to $11 million
• Led by:
  • Mount Sinai Hospital
  • University of Chicago Medicine
  • Sheba Medical Center

Why the DoD Cares?

• Over 35,000 military beneficiaries have IBD
• Ulcerative colitis rates are ~50% higher in military populations

This isn’t just a medical issue, it’s an operational one.

The Core Idea: Combination Therapy

Instead of testing another drug alone, this trial explores something different: A biologic + a nutraceutical

The Combo

• Vedolizumab → an established biologic therapy
• CurQD → Evinature’s plant-based formulation

The goal: Improve response rates by targeting inflammation through multiple pathways

What Is CurQD?

CurQD is not a generic supplement. It’s a clinically studied formulation combining:

• Curcumin (anti-inflammatory compound from turmeric)
• QingDai (indigo naturalis) (traditional plant-based compound)

It has already shown efficacy in a randomized, placebo-controlled trial in ulcerative colitis patients.

Importantly: It’s designed to complement—not replace—pharmaceutical treatment

Why This Approach Makes Sense?

Here’s the problem with current IBD treatment:

• Single-drug strategies hit a response ceiling
• Patients cycle through therapies
• Many never achieve sustained remission

As Ryan Ungaro explains, the goal is simple: Increase the percentage of patients who actually respond.

The Hypothesis

• Biologics target specific immune pathways
• Nutraceuticals may modulate inflammation differently

Combine both → potentially better outcomes

A Shift in Patient Behavior

There’s another driver here: patient demand

More patients are:

• Seeking natural or complementary therapies
• Looking to reduce drug burden
• Interested in holistic treatment approaches

This trial reflects that shift. As researchers note, patients increasingly want integrated care—not just prescriptions.

Scientific Validation of Nutraceuticals Is Growing

Nutraceuticals have long existed in a gray zone. But that’s changing.

Curcumin and QingDai are now:

• Included in 2025 European Crohn’s and Colitis guidelines
• Recognized as adjunctive options

That’s a big step toward mainstream acceptance.

Why This Trial Is Different

Most combination trials in IBD test: Drug + drug

This one tests: Drug + nutraceutical

As Shomron Ben-Horin highlights, this is a novel strategy aimed at improving both:

• Induction of remission
• Long-term maintenance

---

The Bigger Problem: Ulcerative Colitis Burden

Ulcerative colitis isn’t niche.

• ~1.25 million Americans affected
• Peak onset: ages 15–30
• Annual U.S. economic burden: $14.6–$31.6 billion

It’s chronic, disruptive, and expensive. And current therapies don’t work for everyone.

The Bigger Trend: Integrative Medicine Goes Clinical

This trial signals a broader shift:

Moving from alternative medicine → evidence-based integrative medicine

Key changes:

• Nutraceuticals backed by randomized trials
• Institutional adoption (major hospitals involved)
• Government funding support

If successful, this could:

• Redefine treatment guidelines
• Open the door for more hybrid therapies
• Blur the line between pharma and nutrition

Final Takeaway

This isn’t just a clinical trial. It’s a test of a new philosophy: Treat complex diseases with layered approaches, not single solutions

If the combination of CurQD and vedolizumab works, it could:

• Break the 50% response ceiling
• Validate nutraceuticals as serious clinical tools
• Change how ulcerative colitis is treated worldwide

But until results come in, one thing is clear: The industry is finally taking integrative medicine seriously.